Merck & Co., Inc. (NYSE:MRK) Updates FY 2026 Earnings Guidance
by Teresa Graham · The Cerbat GemMerck & Co., Inc. (NYSE:MRK – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 5.040-5.160 for the period, compared to the consensus earnings per share estimate of 5.070. The company issued revenue guidance of $65.8 billion-$67.0 billion, compared to the consensus revenue estimate of $66.5 billion.
Merck & Co., Inc. Stock Performance
Shares of NYSE:MRK traded up $3.12 on Friday, hitting $112.30. The company had a trading volume of 11,951,905 shares, compared to its average volume of 9,163,282. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The stock has a market cap of $277.36 billion, a price-to-earnings ratio of 15.43, a P/E/G ratio of 2.21 and a beta of 0.26. The stock has a 50 day moving average price of $117.69 and a 200 day moving average price of $107.39. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 26.84%. The company’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the company earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts expect that Merck & Co., Inc. will post 4.89 EPS for the current year.
Analyst Ratings Changes
A number of brokerages have recently issued reports on MRK. TD Cowen upped their price objective on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a research report on Tuesday, January 20th. Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. Finally, Citigroup upped their price objective on shares of Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, March 20th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $128.18.
Insider Buying and Selling
In other Merck & Co., Inc. news, CFO Caroline Litchfield sold 41,997 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total transaction of $5,023,261.17. Following the completion of the sale, the chief financial officer owned 90,192 shares of the company’s stock, valued at approximately $10,787,865.12. This represents a 31.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Chirfi Guindo sold 20,000 shares of the stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the sale, the chief marketing officer directly owned 80,615 shares of the company’s stock, valued at $9,825,356.20. This represents a 19.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 320,176 shares of company stock valued at $38,281,735 over the last three months. Insiders own 0.17% of the company’s stock.
Merck & Co., Inc. News Summary
Here are the key news stories impacting Merck & Co., Inc. this week:
- Positive Sentiment: Q1 results beat expectations — Merck posted revenue and adjusted EPS above Street forecasts with Keytruda and Winrevair driving growth; the beats and upbeat commentary lifted investor sentiment. Merck tops Q1 estimates
- Positive Sentiment: Regulatory approvals & pipeline progress expand addressable markets — Merck won FDA approval for a new 2‑drug HIV regimen (IDVYNSO) and EC approval for ENFLONSIA for RSV prevention; the company also dosed the first patient in Phase 3 enpatoran lupus trials, adding long‑term growth optionality. Merck expands beyond oncology
- Neutral Sentiment: Analyst action mixed — Wells Fargo trimmed its price target to $145 but kept an Overweight rating, signaling continued confidence despite a modestly lower PT. Wells Fargo lowers PT
- Neutral Sentiment: FY‑2026 guidance and outlook — Merck provided EPS guidance of $5.04–$5.16 and a narrowed sales view ($65.8B–$67.0B). Guidance is close to consensus but tighter ranges mean less revenue upside visibility near term. Merck Q1 financial results
- Neutral Sentiment: Sector context — Biotech peers are mixed (Moderna saw vaccine revenue rebound but its stock fell; Organon missed), so some moves reflect broader healthcare rotation rather than Merck‑specific news. Moderna Covid vaccine drives growth
- Negative Sentiment: Acquisition-related charge produced a GAAP loss — A Cidara-related charge drove a quarterly GAAP loss, which clouds headline profitability despite the operational beat. Merck posts quarterly loss due to Cidara charge
- Negative Sentiment: Longer-term growth risks flagged — Coverage noted potential future pressure from lost sales on some products (e.g., competitive threats to Keytruda, HPV and diabetes medicines) and Merck said it is working on mitigations. That risk keeps some investors cautious. Merck stock falls after earnings
Institutional Trading of Merck & Co., Inc.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRK. Prosperity Bancshares Inc bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $26,000. IFC & Insurance Marketing Inc. bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $31,000. Safe Harbor Fiduciary LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $32,000. Gilpin Wealth Management LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $32,000. Finally, Wealth Watch Advisors INC bought a new position in shares of Merck & Co., Inc. during the 3rd quarter worth approximately $34,000. Institutional investors and hedge funds own 76.07% of the company’s stock.
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.